BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

57.18 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

19 20 Next >

Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

April 25, 2024

Via Benzinga

Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings) ↗

April 25, 2024

Via Benzinga

3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition ↗

April 25, 2024

Many fortunes have been made with a fortuitous investment in a biotech stock at the right time. That time might be now.

Via InvestorPlace

Looking Into Biomarin Pharmaceutical's Recent Short Interest ↗

April 03, 2024

Via Benzinga

The Latest Analyst Ratings For Biomarin Pharmaceutical ↗

February 23, 2024

Via Benzinga

Recap: Biomarin Pharmaceutical Q4 Earnings ↗

February 22, 2024

Via Benzinga

BMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Misses Revenue for Q1 2024 ↗

April 24, 2024

BMRN stock results show that Biomarin Pharmaceutical beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 24, 2024

Via Benzinga

Don't overlook NASDAQ:BMRN—a stock with solid growth prospects and a reasonable valuation. ↗

April 08, 2024

Investors seeking growth at a reasonable cost should explore BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN).

Via Chartmill

While growth is established for NASDAQ:BMRN, the stock's valuation remains reasonable. ↗

March 18, 2024

Despite its growth, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) remains within the realm of affordability.

Via Chartmill

4 Extraordinary Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market ↗

March 16, 2024

Although the Nasdaq Composite is galloping to record highs, amazing deals among growth stocks can still be uncovered.

Via The Motley Fool

Topics Stocks

Decoding 8 Analyst Evaluations For Biomarin Pharmaceutical ↗

January 30, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical ↗

December 21, 2023

Via Benzinga

Earnings Outlook For Biomarin Pharmaceutical ↗

October 31, 2023

Via Benzinga

Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN. ↗

February 26, 2024

For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.

Via Chartmill

7 Biotech Stocks Fighting America’s Deadliest Diseases ↗

February 08, 2024

Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.

Via InvestorPlace

3 No-Brainer Stocks to Buy With $200 Right Now ↗

February 07, 2024

A reasonably small amount of money can go a long way when it's put to work in innovative, industry-leading businesses.

Via The Motley Fool

4 Marvelous Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

January 20, 2024

A greater than 7% decline in the Nasdaq Composite from its record high signals that opportunistic investors can still find bargains.

Via The Motley Fool

Topics Stocks

If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names ↗

January 10, 2024

Biotech is one of the areas of interest in the market today, adding a biotech stock could be huge play this month.

Via InvestorPlace

15 Analysts Have This to Say About Biomarin Pharmaceutical ↗

October 16, 2023

Via Benzinga

4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

December 02, 2023

An 11% decline in the Nasdaq Composite over the past two years is an open invitation for opportunistic growth investors to go shopping.

Via The Motley Fool

Topics Stocks

Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures ↗

November 09, 2023

Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.

Via InvestorPlace

3 Promising Biotech Stocks Flying Under the Radar ↗

November 08, 2023

Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.

Via InvestorPlace

BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake ↗

November 07, 2023

The company's recently FDA-approved gene therapy is struggling to gain traction.

Via Investor's Business Daily

Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday ↗

November 07, 2023

U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 50 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

4 Unique Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

November 04, 2023

A 19% decline in the Nasdaq Composite over the past two years represents an ideal time for opportunistic long-term investors to go shopping for bargains.

Via The Motley Fool

Topics Stocks

Why Is Gene Therapy Player PTC Therapeutics Stock Plunging Today? ↗

October 27, 2023

In its Q3 earnings release, PTC Therapeutics Inc (NASDAQ: PTCT) reported a

Via Benzinga

3 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

October 19, 2023

These three lesser-known biotech companies are profitable and growing revenue.

Via The Motley Fool

Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty ↗

September 28, 2023

Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023 ↗

September 28, 2023

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.